Skip to main content
. 2024 Jul 17;13(7):3217–3241. doi: 10.21037/tcr-23-2332

Figure 7.

Figure 7

Immune response, and immunotherapy analysis of high- and low-risk subgroups. (A) Enrichment analysis of immune cell infiltration and immune-related pathways. (B) Comparison of immune and estimate scores between the low- and high-risk subgroups. (C) Immune cell bubble of the low- and high-risk subgroups by different algorithms. (D) Association between immune infiltration and riskScore. (E) TMB, NEO, MSI score differed between high- and low-risk subgroups. (F) TIDE and Exclusion scores differed between high- and low-risk subgroups. (G) Checkpoint genes PD-L1 and PD-L2 differed between high- and low-risk subgroups. (H) OS differed between high- and low-risk subgroups in IMvigor210 cohort. (I) OS differed between high- and low-risk subgroups in GSE135222 cohort. (J) IPS differed between high- and low-risk subgroups. (K) Immune subtype differed between high- and low-risk subgroups. *, P≤0.05; **, P≤0.01; ***, P≤0.001. aDCs, activated dendritic cells; DCs, dendritic cells; iDCs, immature dendritic cells; NK, natural killer; pDCs, plasmacytoid dendritic cells; Tfh, T follicular helper; Th, T helper; TIL, tumor-infiltrating lymphocyte; Treg, regulatory T cell; TCGA, The Cancer Genome Atlas; LUAD, lung adenocarcinoma; TMB, tumor mutational burden; NEO, neoantigen; MSI, microsatellite instability; TIDE, Tumor Immune Dysfunction and Exclusion; OS, overall survival; IPS, immunophenoscore.